Streetbeat News

Products Services

TSLA

Tech analyst Dan Ives from Wedbush expects Tesla's Q3 deliveries to exceed expectations, driven by strong demand in China. He anticipates positive catalysts like the upcoming Robotaxi event and believes Tesla's price cuts are mostly over, with gross margins set to rebound. Wedbush maintains an Outperform rating and a $300 price target for Tesla.

Portfolio Pulse from Erica Kollmann

September 27, 2024 | 5:02 pm

BLNK

WBAT

Blink Charging Co. (NASDAQ:BLNK) shares rose after surpassing 100,000 EV chargers sold, deployed, or contracted globally. The company attributes this success to its turnkey model and maintenance programs. Blink plans to lay off 14% of its workforce to cut costs. The stock has a 1-year price target of $5.12, with no bearish analyst recommendations.

Portfolio Pulse from Lekha Gupta

September 27, 2024 | 4:55 pm

ESLA

Estrella Immunopharma's shares are trading lower despite announcing a complete response from its first patient treated with Cd19-redirected artemis t-cells.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 4:39 pm

GD

ITA

NOC

PPA

TDG

XAR

The Biden administration's decision to provide Ukraine with long-range missiles has raised concerns about potential Russian retaliation. Germany has pledged $78 million in winter aid to Ukraine. Defense stocks and ETFs saw mixed movements following the news.

Portfolio Pulse from Anthony Noto

September 27, 2024 | 4:34 pm

BMEA

The FDA has lifted the clinical hold on Biomea Fusion's Phase 1/2 trials for their diabetes treatment candidate BMF-219, following a safety review. The trials had been paused due to concerns over potential liver toxicity. Biomea Fusion's stock saw a slight increase following the news.

Portfolio Pulse from Vandana Singh

September 27, 2024 | 4:20 pm

BP

SLB

XOM

Energy stocks are rising as oil prices increase following an Israeli airstrike on Hezbollah in Beirut. Israeli PM Netanyahu emphasized the right to address threats, impacting the energy sector.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 4:20 pm

ABBV

AbbVie has submitted a Biologics License Application to the FDA for Teliso-V, an investigational drug for previously treated non-small cell lung cancer with c-Met protein overexpression. If approved, it would be the first therapy for this specific cancer type.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 4:15 pm

JNJ

Johnson & Johnson released updated data from two early-stage studies on Talvey combo treatments for multiple myeloma, showing promising response rates and progression-free survival. The studies, RedirecTT-1 and TRIMM-2, demonstrated high overall response rates and complete response rates in patients with relapsed or refractory multiple myeloma.

Portfolio Pulse from Vandana Singh

September 27, 2024 | 4:14 pm

SONM

Sonim Technologies has partnered with Brodos AG to expand its rugged mobile solutions in the DACH region, which includes Germany, Austria, and Switzerland. This strategic partnership aims to enhance Sonim's market presence in these countries.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 4:10 pm

TNXP

Tonix Pharmaceuticals (NASDAQ:TNXP) shares rose 17.2% after the company received a patent for subcutaneous delivery of Zembrace Symtouch for migraines, valid until 2036. This follows a campaign promoting non-oral migraine treatments.

Portfolio Pulse from Dylan Berman

September 27, 2024 | 4:10 pm